Gulf Pharmaceutical Industries P.S.C.'s (ADX:JULPHAR) Price Is Right But Growth Is Lacking

With a price-to-sales (or "P/S") ratio of 0.6x Gulf Pharmaceutical Industries P.S.C. (ADX:JULPHAR) may be sending bullish signals at the moment, given that almost half of all the Pharmaceuticals companies in the United Arab Emirates have P/S ratios greater than 2.4x and even P/S higher than 6x are not unusual. However, the P/S might be low for a reason and it requires further investigation to determine if it's justified.

View our latest analysis for Gulf Pharmaceutical Industries P.S.C

How Gulf Pharmaceutical Industries P.S.C Has Been Performing

Gulf Pharmaceutical Industries P.S.C could be doing better as it's been growing revenue less than most other companies lately. Perhaps the market is expecting the current trend of poor revenue growth to continue, which has kept the P/S suppressed. If you still like the company, you'd be hoping revenue doesn't get any worse and that you could pick up some stock while it's out of favour.

Want the full picture on analyst estimates for the company? Then our free report on Gulf Pharmaceutical Industries P.S.C will help you uncover what's on the horizon.

Is There Any Revenue Growth Forecasted For Gulf Pharmaceutical Industries P.S.C?

There's an inherent assumption that a company should underperform the industry for P/S ratios like Gulf Pharmaceutical Industries P.S.C's to be considered reasonable.

If we review the last year of revenue, the company posted a result that saw barely any deviation from a year ago. Despite the lack of growth, the company was still able to deliver immense revenue growth over the last three years. Accordingly, shareholders will be pleased, but also have some serious questions to ponder about the last 12 months.

Shifting to the future, estimates from the lone analyst covering the company suggest revenue should grow by 5.8% over the next year. That's shaping up to be materially lower than the 22% growth forecast for the broader industry.

With this information, we can see why Gulf Pharmaceutical Industries P.S.C is trading at a P/S lower than the industry. It seems most investors are expecting to see limited future growth and are only willing to pay a reduced amount for the stock.

The Bottom Line On Gulf Pharmaceutical Industries P.S.C's P/S

Typically, we'd caution against reading too much into price-to-sales ratios when settling on investment decisions, though it can reveal plenty about what other market participants think about the company.

We've established that Gulf Pharmaceutical Industries P.S.C maintains its low P/S on the weakness of its forecast growth being lower than the wider industry, as expected. Shareholders' pessimism on the revenue prospects for the company seems to be the main contributor to the depressed P/S. Unless these conditions improve, they will continue to form a barrier for the share price around these levels.

Before you settle on your opinion, we've discovered 1 warning sign for Gulf Pharmaceutical Industries P.S.C that you should be aware of.

If you're unsure about the strength of Gulf Pharmaceutical Industries P.S.C's business, why not explore our interactive list of stocks with solid business fundamentals for some other companies you may have missed.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.